Ghulam Hassam U. Din Tarrar

Resmetirom: A New FDA-approved Drug as a Targeted Therapeutic Strategy in Metabolic Dysfunction Associated Steatohepatitis: Translational Evidence from Current Clinical Trials.

Metabolic dysfunction-associated steatohepatitis (MASH) represents a significant global health burden, affecting 3-5% of the population and projected to become a leading cause of liver transplantation by 2030. This review examines Resmetirom, the first FDA-approved drug for non-cirrhotic MASH with moderate to severe he...